Selection of Sensitive Methylation Markers for the Detection of Non-small Cell Lung Cancer

Zhao, Xia; Jen, Jin; Peikert, Tobias

doi:10.4172/2155-9929.1000250

Cited by 4 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High HOXA9 methylation levels were previously reported in NSCLC [19,20,21,27], but to the best of our knowledge, this is the first study demonstrating higher HOXA9 methylation levels in SCLC tissue and ccfDNA samples. Moreover, higher HOXA9 methylation levels were found in SCC compared to AdC in tissue samples, confirming previous studies [43,44].…”

Section: Discussionsupporting

confidence: 90%

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies

Nunes

Diniz

Moreira-Barbosa

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Lung cancer (LCa) is the most frequently diagnosed and lethal cancer worldwide. Histopathological subtyping, which has important therapeutic and prognostic implications, requires material collection through invasive procedures, which might be insufficient to enable definitive diagnosis. Aberrant DNA methylation is an early event in carcinogenesis, detectable in circulating cell-free DNA (ccfDNA). Herein, we aimed to assess methylation of selected genes in ccfDNA from LCa patients and determine its accuracy for tumor subtyping. Methods: Methylation levels of APC, HOXA9, RARβ2, and RASSF1A were assessed in three independent study groups (study group #1: 152 tissue samples; study group #2: 129 plasma samples; study group #3: 28 benign lesions of lung) using quantitative methylation-specific PCR. Associations between gene promoter methylation levels and LCa subtypes were evaluated using non-parametric tests. Receiver operating characteristic (ROC) curve analysis was performed. Results: In study group #2, HOXA9 and RASSF1A displayed higher methylation levels in small-cell lung cancer (SCLC) than in non-small-cell lung cancer (NSCLC). HOXA9 displayed high sensitivity (63.8%), whereas RASSF1A disclosed high specificity (96.2%) for SCLC detection in ccfDNA. Furthermore, HOXA9 methylation levels showed to be higher in squamous cell carcinoma in comparison with adenocarcinoma in study group #1. Conclusions: Methylation level assessments in ccfDNA may provide a minimally invasive procedure for LCa subtyping, complementing standard diagnostic procedures.

show abstract

Section: Discussionsupporting

confidence: 90%

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies

Nunes

Diniz

Moreira-Barbosa

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Each plate consisted of bisulfite-treated DNA samples, positive and negative controls, and water blanks. For cell line and tissue samples, the methylation level of SDC2 gene was defined as the ratio of the copy number of SDC2 to that of ACTB and multiplied by 100 (22). For stool samples, the quantified strand number of methylated SDC2 was used to calculate marker performance.…”

Section: Real-time Mspmentioning

confidence: 99%

Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia

Niu

Wen

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

105

View full text Add to dashboard Cite

Although the incidence of colorectal cancer is steadily increasing, screening for colorectal cancer with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. is frequently methylated in colorectal cancer. However, the value of a stool test of methylated for the detection of colorectal cancer is unknown. Methylation status of was tested in cell lines and 398 colorectal tissue samples and further evaluated with 497 stool samples, including 196 from colorectal cancer patients, 122 from adenoma patients, and 179 from normal individuals, using real-time methylation-specific PCR. The impacts of one quantitative partial stool sampling device and 17 potentially interfering substances on the performance of fecal methylated were also analyzed. expression was also measured. methylation level was higher in 96.8% (120/124) of colorectal cancer tissues compared with paired adjacent normal epithelia. Stool test of methylated detected 81.1% (159/196) of colorectal cancer and 58.2% (71/122) of adenomas at a specificity of 93.3% (167/179). No significant difference was found between partial and whole stool collection on colorectal cancer detection ( > 0.05, = 0.80). Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated was overexpressed in colorectal cancer tissues compared with normal epithelia. Fecal methylated is a valuable biomarker for the noninvasive detection of colorectal neoplasms. Stool DNA test of methylated would serve as an alternative method for screening colorectal neoplasms..

show abstract

“…Therefore, differences in DNAm patterns are expected and could potentially be exploited for better diagnosis and personalized treatments. Previous studies interrogating a list of selected genes suggest that methylation rates of ANK1 , APC , CCND2 , CDH13 , GATA3 , KCNH5 , LINE-1 , RARβ , RASSF1 , and RUNX3 are significantly higher in LUAD than in LUSC [ 13 , 17 , 136 , 137 , 138 ], while higher methylation frequencies of AGTR1 , CDKN2A/P16 , DAPK , HOXA9, MLH1 , SHOX2 , SFMTB2 , SFRP4 , TIMP3 , TGIF , and ZIC4 , are more often observed in LUSC compared to LUAD [ 13 , 94 , 98 , 102 , 139 , 140 , 141 , 142 ]. An early study using HumanMethylation27 BeadChips to examine 48 stage-I NSCLC tumors identified 263 hypermethylated CpG sites, and 513 hypomethylated CpG sites in LUSC compared to LUAD tumors [ 12 ].…”

Section: Dna Methylation In Different Histological Subtypesmentioning

confidence: 99%

DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors

Hoang

Landi

2022

Cancers

View full text Add to dashboard Cite

Lung cancer is the major leading cause of cancer-related mortality worldwide. Multiple epigenetic factors—in particular, DNA methylation—have been associated with the development of lung cancer. In this review, we summarize the current knowledge on DNA methylation alterations in lung tumorigenesis, as well as their associations with different histological subtypes, common cancer driver gene mutations (e.g., KRAS, EGFR, and TP53), and major epidemiological risk factors (e.g., sex, smoking status, race/ethnicity). Understanding the mechanisms of DNA methylation regulation and their associations with various risk factors can provide further insights into carcinogenesis, and create future avenues for prevention and personalized treatments. In addition, we also highlight outstanding questions regarding DNA methylation in lung cancer to be elucidated in future studies

show abstract

Selection of Sensitive Methylation Markers for the Detection of Non-small Cell Lung Cancer

Cited by 4 publications

References 36 publications

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies

Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia

DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors

Contact Info

Product

Resources

About